Literature DB >> 7840214

Expression of muscarinic receptor subtypes and M2-muscarinic inhibition of adenylyl cyclase in lung.

C W Emala1, A Aryana, M A Levine, R P Yasuda, S A Satkus, B B Wolfe, C A Hirshman.   

Abstract

The relative distribution and absolute quantities of muscarinic receptor subtypes m1, m2, m3, and m4 were determined in membranes of canine trachealis muscle, bronchi, and lung parenchyma by immuno-precipitation with receptor subtype-specific rabbit polyclonal antisera. Additionally, the functional coupling of muscarinic receptors to the inhibition of adenylyl cyclase was related to the presence of m2-muscarinic receptors in each region. Immunoprecipitation identified more total muscarinic receptors in trachealis muscle than in bronchi or lung. m2-Muscarinic receptor predominated in tracheal muscle (372 +/- 85 fmol/mg protein) with fewer m3 receptors (48 +/- 5 fmol/mg protein). Bronchi contained 6.6 +/- 2.0 and 9.2 +/- 1.8 fmol/mg protein of m2 and m3 receptors, respectively. Lung parenchyma contained 13.9 +/- 3.9 fmol/mg protein of m3 receptors. Adenylyl cyclase activity increased in response to guanosine triphosphate and isoproterenol in membranes from all three lung regions, but muscarinic-mediated inhibition of adenylyl cyclase occurred only in trachealis membranes. These studies provide the first quantitative assessment of muscarinic receptor subtypes in different regions of the lung and relate the ability to measure muscarinic inhibition of adenylyl cyclase to the presence of m2 receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840214     DOI: 10.1152/ajplung.1995.268.1.L101

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  3 in total

1.  Segment-dependent expression of muscarinic acetylcholine receptors and G-protein coupling in the equine respiratory tract.

Authors:  G Abraham; C Kottke; H Ammer; S Dhein; F R Ungemach
Journal:  Vet Res Commun       Date:  2006-12-15       Impact factor: 2.459

2.  Chronic pulmonary LPS tolerance induces selective immunosuppression while maintaining the neutrophilic response.

Authors:  Sudha Natarajan; Jiyoun Kim; Daniel G Remick
Journal:  Shock       Date:  2010-02       Impact factor: 3.454

Review 3.  Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Authors:  Alejandro Español; Agustina Salem; Yamila Sanchez; María Elena Sales
Journal:  World J Clin Oncol       Date:  2021-06-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.